PromarkerEso, a blood test for early detection of esophageal cancer was launched in Australia on 18 September at the ISDE World Congress.
New results, published in Diseases of the Esophagus, have confirmed high diagnostic accuracy across all EAC stages, addressing a critical need given the disease’s low 20% five-year survival rate.
The test leverages the same logistics as PromarkerD, with US preparations underway via Proteomics’ CLIA-certified lab in Irvine.
CLIA certification ensures that laboratories performing diagnostic testing on human samples meet stringent quality, accuracy, and reliability standards for clinical testing.
PromarkerEndo, which targets endometriosis diagnosis, is on track for a second half 2025 Australian launch and should add further to Proteomics now developing sales pipeline.
An expanded collaboration with the University of Melbourne and Royal Women’s Hospital will advance clinical validation and develop a tissue-specific test, addressing a condition that affects one in nine women and incurs a massive annual cost of $9.7 billion.
OxiDx, a test for oxidative stress, has shown promise in a Veterinary Science and Medicine study, tracking muscle recovery in racehorses. With applications in sports and equine industries, OxiDx is also slated for a second half 2025 launch. Analytical services, including pharmacokinetic and biomarker analysis, continue to generate steady revenue.
Proteomics customer receipts for the quarter were $1.86m, of which $1.71 million was a non-recurring payment from a WA Proteomics Facility partnership with UWA.
With commercialisation now under way, Proteomics founder and Managing Director Dr. Richard Lipscombe has announced his impending retirement in February 2026 and a global search for a new CEO underway.
With strong cash reserves, strategic partnerships and a pipeline of product either just in the market or coming to market soon, Proteomics looks set for a new journey now that should be punctuated by cashflows.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
